NASDAQ · DOMH
Dominari Holdings Inc.
$1.72-$0.03 (-1.71%)
Dominari Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.88% below the high.
Loading market information…
NASDAQ · ELEV · USD
Stock price, earnings
Quote as of Jul 23, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Elevation Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.19% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Elevation Oncology, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study focuses on treating advanced solid tumors that harbor a neuregulin-1 fusion. The company was established in 2019 and is headquartered in New York, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Nov 2, 2023 |
| -$0.25+26.47% vs estimate |
| $0.00 |
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.72-$0.03 (-1.71%)
Dominari Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.88% below the high.
$4.30-$0.14 (-3.15%)
AnPac Bio-Medical Science Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 64.14% below the high.
$0.63$0.00 (0.0%)
LakeShore Biopharma Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 92.71% below the high.
$0.21+$0.01 (+5.66%)
Renalytix Plc’s quoted price sits in the lower half of its reported 52-week range, 91.37% below the high.
$3.07+$0.29 (+10.43%)
MEI Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.89% below the high.
$3.10-$0.17 (-5.2%)
PHAXIAM Therapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 76.15% below the high.
$13.60-$2.51 (-15.58%)
Pieris Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.07% below the high.
$1.21+$0.02 (+1.68%)
MetaVia Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.85% below the high.
